Angiodysplasia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nikita Singh, M.B.B.S.[2]

Angiodysplasia: cost-effectiveness of therapy

Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for bleeding lesions. Pharmacological therapies are also cost-effective for patients with significant co-morbidities who cannot undergo endoscopic therapy.^[1]^[2]

References

↑ Olmos JA, Marcolongo M, Pogorelsky V, Herrera L, Tobal F, Dávolos JR (2006). “Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia”. Dis Colon Rectum. 49 (10): 1507–16. doi:10.1007/s10350-006-0684-1. PMID 17024322.
↑ Sami SS, Al-Araji SA, Ragunath K (2014). “Review article: gastrointestinal angiodysplasia – pathogenesis, diagnosis and management”. Aliment Pharmacol Ther. 39 (1): 15–34. doi:10.1111/apt.12527. PMID 24138285.

[pmid17024322-1] Olmos JA, Marcolongo M, Pogorelsky V, Herrera L, Tobal F, Dávolos JR (2006). “Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia”. Dis Colon Rectum. 49 (10): 1507–16. doi:10.1007/s10350-006-0684-1. PMID 17024322.

[pmid24138285-2] Sami SS, Al-Araji SA, Ragunath K (2014). “Review article: gastrointestinal angiodysplasia – pathogenesis, diagnosis and management”. Aliment Pharmacol Ther. 39 (1): 15–34. doi:10.1111/apt.12527. PMID 24138285.

[1]

[2]